Guy's Hospital-ko ikertzaileekin lankidetzan egindako argitalpenak (17)

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Erratum to: Mapping the human genetic architecture of COVID-19 (Nature, (2021), 600, 7889, (472-477), 10.1038/s41586-021-03767-x)

    Nature

2021

  1. Age-sex specific pulmonary embolism-related mortality in the USA and Canada, 2000–18: an analysis of the WHO Mortality Database and of the CDC Multiple Cause of Death database

    The Lancet Respiratory Medicine, Vol. 9, Núm. 1, pp. 33-42

  2. Incidence of VTE and Bleeding Among Hospitalized Patients With Coronavirus Disease 2019: A Systematic Review and Meta-analysis

    Chest, Vol. 159, Núm. 3, pp. 1182-1196

  3. Mapping the human genetic architecture of COVID-19

    Nature, Vol. 600, Núm. 7889, pp. 472-477

  4. SARS-CoV-2 Vaccine and Thrombosis: An Expert Consensus on Vaccine-Induced Immune Thrombotic Thrombocytopenia

    Thrombosis and Haemostasis, Vol. 121, Núm. 8, pp. 982-991

2020

  1. ETNA VTE Europe: A contemporary snapshot of patients treated with edoxaban in clinical practice across eight European countries

    European Journal of Internal Medicine, Vol. 82, pp. 48-55

  2. ETNA-VTE Europe: Benefits and risks of venous thromboembolism treatment using edoxaban in the first 3 months

    Thrombosis Research, Vol. 196, pp. 297-304

2019

  1. Health-related quality of life and mortality in patients with pulmonary embolism: a prospective cohort study in seven European countries

    Quality of Life Research, Vol. 28, Núm. 8, pp. 2111-2124

2018

  1. Correction: Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study [Thrombosis Journal, 16, (2018) (9)] DOI: 10.1186/s12959-018-0163-7

    Thrombosis Journal

  2. Design and rationale of the non-interventional, edoxaban treatment in routiNe clinical prActice in patients with venous ThromboEmbolism in Europe (ETNA-VTE-Europe) study

    Thrombosis Journal, Vol. 16, Núm. 1

  3. Pulmonary embolism in Europe - Burden of illness in relationship to healthcare resource utilization and return to work

    Thrombosis Research, Vol. 170, pp. 181-191

2017

  1. Comparison of fatal or irreversible events with extended-duration betrixaban versus standard dose enoxaparin in acutely Ill medical patients: An APEX trial substudy

    Journal of the American Heart Association, Vol. 6, Núm. 7

  2. Sex differences in the characteristics and short-term prognosis of patients presenting with acute symptomatic pulmonary embolism

    PLoS ONE, Vol. 12, Núm. 11

2016

  1. Extended thromboprophylaxis with betrixaban in acutely ill medical patients

    New England Journal of Medicine, Vol. 375, Núm. 6, pp. 534-544

  2. Risk stratification of patients with acute symptomatic pulmonary embolism based on presence or absence of lower extremity DVT: Systematic review and meta-Analysis

    Chest, Vol. 149, Núm. 1, pp. 192-200

2015

  1. The management of acute venous thromboembolism in clinical practice - study rationale and protocol of the European PREFER in VTE Registry

    Thrombosis Journal, Vol. 13, Núm. 1